Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) Director William D. Waddill sold 8,000 shares of the firm’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $35.00, for a total transaction of $280,000.00. Following the completion of the transaction, the director now directly owns 12,000 shares […]
E Fund Management Co. Ltd. Sells 9,034 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Increased to $45.00 by Analysts at JMP Securities tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.
Obermeyer Wood Investment Counsel Lllp lessened its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 12.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,066 shares of the company’s stock after selling 1,726 shares during the quarter. Obermeyer Wood Investment […]
Bank of New York Mellon Corp raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) by 3.6% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,073,815 shares of the biotechnology company’s stock after acquiring an additional 37,243 shares during the period. Bank of New York […]